Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.77 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.77 |
| ▸ | HEXA | P06865 | 5/20 | 0.74 |
| ▸ | HEXB | P07686 | 5/20 | 0.74 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amonafide SCHEMBL29352008 | 1.00 | FTO (1.00) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL6255345 | 1.00 | FTO (1.00) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1049714 | 0.99 | FTO (0.97) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1566668 | 0.99 | FTO (0.97) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1051955 | 0.99 | FTO (0.97) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL20242315 | 0.94 | FTO (0.88) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1566374 | 0.93 | FTO (0.86) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL9144516 | 0.93 | FTO (0.86) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1565520 | 0.93 | FTO (0.86) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL5164837 | 0.92 | FTO (0.84) | FTOCYP2D6POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8653 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| EP-4608801-A1 | ANTICANCER DRUG CONJUGATES | Ariel Scientific Innovations Ltd. (IL) | 2025-09-03 | — | — | EP | claimed |
| WO-2025129074-A2 | INDEXING TECHNIQUES FOR TAGMENTED DNA LIBRARIES | ILLUMINA, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4525855-A1 | INTERCALATING SUGAR MOLECULES | Xalud Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119285689-A | Galactoside antitumor prodrug intermediate, and preparation and application thereof | 江南大学 | 2025-01-10 | — | — | CN | claimed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | claimed |
| WO-1995004757-A1 | USE OF MONOCLONAL ANTIBODIES FOR DETERMINING SENSITIVITY TO ACETYLIZABLE DRUGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-02-16 | — | — | WO | claimed |
| EP-0482043-B1 | Monohydrochloride and monomethansulphonate of amonafide. | KNOLL AG (DE) | 1994-09-28 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0482043-A1 | Monohydrochloride and monomethansulphonate of amonafide. | KNOLL AG (DE) | 1992-04-29 | — | — | EP | claimed |
| US-5057304-A | Anticarcinogenic agents | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-15 | — | — | US | claimed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | claimed |
| WO-1991000857-A1 | AMONAFIDE SALTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1991-01-24 | — | — | WO | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |